Editas Medicine, Inc. EDIT incurred a loss of 81 cents per share in the third quarter of 2022, narrower than the Zacks Consensus Estimate of a loss of 87 cents. The company had reported a loss of 57 ...
Editas Medicine, Inc. EDIT incurred a loss of 55 cents per share in the third quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 64 cents per share. The company had reported a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results